Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07553377 · ClinicalTrials.gov registry record · NA
A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease
A NA study, sponsored by Yale University.
- Not yet
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT07553377 is a NA study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 50 participants.
The verdict
NCT07553377, a NA study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study seeks to develop and test a novel digital pill system (DPS) that measures real-time medication ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention to provide personalized, data-driven adherence support, with the long-term goal of providing new and improved personalized support and increase medication adherence for people with AUD and ALD.
Interventions
- DEVICE AcamproSync
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2027-10 |
| Est. Completion | 2030-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07553377
The ClinicalTrials.gov registry entry for NCT07553377 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AcamproSync is the first listed.
NCT07553377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07553377 about?
NCT07553377 is a clinical study titled "A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease". This study seeks to develop and test a novel digital pill system (DPS) that measures real-time medication ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention to provide personalized, data-driven adherence support, with the long-term goal of providing new and improved ...
What is the current status of trial NCT07553377?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2027-10. Estimated completion is 2030-10.
What interventions are being tested in trial NCT07553377?
The interventions under investigation include: AcamproSync (DEVICE).
Who is sponsoring clinical trial NCT07553377?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.